Neuron23® Inc., a clinical-stage biotechnology company focused on developing precision medicines for genetically defined ...

Approximately 150 subjects will be enrolled, receiving either the therapy or a placebo daily for a 52-week treatment period.

Denali Therapeutics remains an intriguing clinical-stage biotech focused on neurodegenerative and lysosomal storage diseases.

NEULARK trial to evaluate NEU-411, a brain-penetrant, potent and selective LRRK2 inhibitor, in people with LRRK2-driven Parkinson’s disease; topline data anticipated in 2027 SOUTH SAN FRANCISCO ...

A large longitudinal study found that pesticide exposure and caffeinated soda intake were linked to more severe motor ...

Completion of SAD/MAD trial marks advancement toward further clinical development of HT-4253 in Alzheimer's and other ...

About LRRK2’s Role in Parkinson’s Disease and NEU-411. Mutations in the LRRK2 gene are among the most common genetic causes of PD, affecting approximately 2% of people with the disease.

HT-4253 is a selective, orally administered LRRK2 kinase inhibitor that pharmacologically reduces phosphorylated Rab10 (pRab10), a biomarker associated with neuroinflammatory processes.

US clinical-stage biotech Neuron23 announced it has closed a $96.5 million Series D financing round and provided an update on ...